De Novo Everolimus-Based Therapy in Renal Transplant Recipients: Effect on Proteinuria and Renal Prognosis

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1297-1302

  Loriga, G ^a   Ciccarese, M ^a   Pala, P G ^a   Satta, R P ^a   Fanelli, V ^a   Manca, M L ^a   Serra, G ^a   Dessole, P ^a   Cossu, M ^a  

^a Azienda Sanitaria Locale di Sassari   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; MORNING DOSAGE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SINGLE DRUG DOSE;

ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROGNOSIS; PROTEINURIA; SAMPLE SIZE; SIROLIMUS;

EID: 77952556721     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.120     Document Type: Article

References (16)

1. Handinger K.L., Koch M.J., and Brennan D.C. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 24 (2004) 1159
2. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 21 suppl 3 (2006) iii18
3. Mulay A.V., Hussain N., Fergusson D., et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5 (2005) 1748
4. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626
5. Vitko S., Margreiter R., Weimar W., et al. RAD B201 Study Group: Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5 (2005) 2521
6. Pascual J., Boletis I.N., and Campistol J.M. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage and future directions. Transplantation Rev 20 (2006) 1
7. Knoll G.A. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis 54 (2009) 1131
8. Dickmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
9. Keane W.F. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 35 (2000) S97
10. Bertoni E., Bruschi M., Candiano G., et al. Posttransplant proteinuria associated with everolimus. Transplant Proc 41 (2009) 1216
11. Vogelbacher R., Wittmann S., Braun A., et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84 (2007) 1492
12. Halloran P., Mathew T., Tomlanovich S., et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Rena Transplat Study Groups. Tranplantation 63 (1997) 39
13. Kaufman D.B., Shapiro R., Lucey M.R., et al. Immunosuppression: practice and trends. Am J Transplant 4 suppl 9 (2004) 38
14. Nashan B., Curtis J., Ponticelli C., et al., 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-years phase II, randomized, multicenter, open-label study. Transplantation 78 (2004) 1332
15. Tedesco-Silva Jr. H., Vitko S., Pasqual J., et al., 2306 and 2307 study group. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in the novo renal transplant recipients. Transpl Int 20 (2007) 27
16. Salvadori M., Scolari M.P., Bertoni E., et al. Everolimus with very low-exposure Cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 88 (2009) 1194